Intravesical BCG Therapy Contraindications and Management

Contraindications and Risks

Active tuberculosis is explicitly listed as a contraindication for intravesical BCG therapy, as it can potentially cause systemic infection 1
Increased risk of BCG sepsis is a concern in patients with positive TB testing, requiring immediate cessation of treatment and intensive care management 2
Possible reduced effectiveness of the treatment due to pre-existing TB immunity is a consideration in patients with positive TB testing 1

The National Comprehensive Cancer Network recommends considering alternative intravesical chemotherapy options, such as Mitomycin C, for patients with positive TB testing who need treatment for non-muscle invasive bladder cancer 3
Mitomycin C is the most commonly recommended alternative, with other options including gemcitabine, epirubicin, or doxorubicin based on efficacy rankings 4, 3
If BCG is absolutely necessary, prophylactic anti-tuberculosis therapy should be considered before starting BCG, with close monitoring for signs of systemic infection 2

Fever >38.5°C for >48 hours requires suspension of BCG instillations, with urine cultures for bacteria and acid-fast bacilli if complications occur 2
BCG sepsis management involves immediately stopping BCG treatment, transferring to ICU, administering broad-spectrum antibiotics, anti-tuberculosis drugs, and corticosteroids 2
The timing of BCG initiation should be considered, with a recommended start at least 2 weeks after TURBT to reduce infection risk 2

The risk-benefit ratio of using BCG in patients with positive TB testing must be carefully considered, especially given the availability of alternative intravesical agents 1, 3